Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation

Xuesen Zhang§, Michael Bolt§, Michael J. Guertin, Wei Chen§, Sheng Zhang§, Brian D. Cherrington, Daniel J. Slade, Christina J. Dreyton, Venkataraman Subramanian, Kevin L. Bicker, Paul R. Thompson, Michael A. Mancini, John T. Lis‡, and Scott A. Coonrod*§

+Department of Animal Health, *Department of Molecular and Genetics, and ‡Proteomics and Mass Spectrometry Core Facility, Cornell University, Ithaca, NY 14853; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; and Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458

Edited by Jerry L. Workman, Stowers Institute for Medical Research, Kansas City, MO, and accepted by the Editorial Board July 2, 2012 (received for review February 24, 2012)

Cofactors for estrogen receptor α (ERα) can modulate gene activity by posttranslationally modifying histone tails at target promoters. Here, we found that stimulation of ERα-positive cells with 17β-estradiol (E2) promotes global citrullination of histone H3 arginine 26 (H3R26) on chromatin. Additionally, we found that the H3 citrulline 26 (H3Cit26) modification colocalizes with ERα at decondensed chromatin loci surrounding the estrogen-response elements of target promoters. Surprisingly, we also found that citrullination of H3R26 is catalyzed by peptidylarginine deiminase (PAD) 2 and not by PAD4 (which citrullinates H4R3). Further, we showed that PAD2 interacts with ERα after E2 stimulation and that inhibition of either PAD2 or ERα strongly suppresses E2-induced H3R26 citrullination and ERα recruitment at target gene promoters. Collectively, our data suggest that E2 stimulation induces the recruitment of PAD2 to target promoters by ERα, whereby PAD2 then citrullinates H3R26, which leads to local chromatin decondensation and transcriptional activation.

Results and Discussion

Estrogen Induces H3R26 Citrullination in Cellulo and in Vivo. To begin testing for associations between histone citrullination and E2 signaling, we first investigated whether estrogen stimulation globally induced citrullination of specific histone arginine residues in MCF-7 breast cancer cells by using confocal immunofluorescence with three different site-specific anticitrullinated histone antibodies: anti-H3Cit2/8/17, anti-H3Cit26, and anti-H4Cit3. Results showed that 45 min of E2 treatment induced a pronounced increase of H3Cit26 in the nuclei of cells (Fig. S1), whereas staining with the two other anticitrullinated histone antibodies was not visibly affected (Fig. S2 A and B). Interestingly, after E2 stimulation, we also did not observe global differences in three other histone modifications known to be altered at specific promoters by E2: H4K5acetyl, H3K9dimethyl, and H3K27trimethyl (Fig. S2 C–E). Further, the increase in H3Cit26 levels was observed as early as 5 min after E2 stimulation and appeared to peak at 45 min (Fig. S3). This time frame is consistent with recent reports on the dynamics of estrogen signaling whereby changes in the MCF-7 cell transcriptome were observed by GRO-seq analysis within 10 min of E2 stimulation (14).

Given these exciting results, and the relatively uncharacterized nature of the anti-H3Cit26 antibody, we next further validated the specificity of this antibody by treating MCF-7 cell histones with recombinant human PAD2 and then immunoblotting the resolved proteins with the H3Cit26 antibody (Note: Our rationale for using PAD2 as opposed to PAD4 is described below). Results (Fig. S4) show that this antibody was reactive with an appropriately sized band from the PAD2-citrullinated histones but was not reactive with untreated histones. Further, we also found that preincubation of the anti-H3Cit26 antibody with the cognate citrullinated peptide nearly completely blocked detection of the H3Cit26 modification. The protein band corresponding to the mass of the citrullinated histone was then excised from the gel and evaluated by mass spectroscopic (MS) analysis. Results show that citrulline was readily detected on histone H3 peptides (24-AAR


The authors declare no conflict of interest.

This article is a PNAS Direct Submission. J.L.W. is a guest editor invited by the Editorial Board.

Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE32599).

1Present address: Department of Zoology and Physiology, University of Wyoming, Laramie, WY 82071.

2To whom correspondence should be addressed. E-mail: sac269@cornell.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1203280109/-/DCSupplemental.
[CitK][acetyl]SAPATGGVK-36) from the PAD2-treated sample (Fig. S4F). We note here that the H3Cit26 modification only occurred on H3 peptides that contained an acetyl modification at lysine-27, thus raising the possibility that a functional “cross talk” exists between the H3Cit26 and H3K27acetyl modifications. This hypothesis will be further tested in the future. To confirm that the anti-H3Cit26 antibody was not recognizing other citrullinated residues on chromatin, we also preblocked the anti-H3Cit26 antibody by using unmodified H3 (19–38), H3Cit26, or H3Cit2/8/17 peptides and then performed chromatin immunoprecipitation (ChIP) analysis on the ERE promoter region. Results (Fig. S4C) showed that only the H3Cit26 peptide abolished the detection of H3Cit26 at the ERE. Taken together, these results strongly suggest that the H3Cit26 antibody is specifically reactive with the H3Cit26 modification.

To investigate whether our findings may have physiological relevance in vivo, we next treated ovariectomized mice with exogenous E2 pellets and then carried out immunohistochemical analysis of uterine tissue (a major E2 target) by using the anti-H3Cit26 antibody. As predicted, relative to vehicle-treated animals, we observed a strong increase in H3Cit26 staining in the nucleus of uterine epithelial cells after E2 treatment (Fig. 1A). Therefore, both our in vitro and in vivo observations strongly suggest that citrullination of histone H3R26 is specifically and globally induced by estrogen signaling.

**Estrogen-Induced H3R26 Citrullination Is Associated with ER Activity.**

Given that the effects of E2 on gene regulation are primarily mediated by ER, we next investigated the relationship between H3Cit26 and ER in cells. After E2 stimulation, immunofluorescence analysis showed a strong colocalization between H3Cit26 and ER in MCF-7 cells (Fig. 1B). In ER-negative MDA-MB231 breast cancer cells, however, citrullination of H3R26 was not observed, either before or after E2 stimulation (Fig. 1C). We further confirmed the requirement of ER for H3R26 citrullination by using HeLa cells, which are also ER negative (Fig. 1D). As expected, H3R26 citrullination was not observed in these cells either before or after E2 treatment. However, in HeLa cells that stably overexpress recombinant ER, E2 stimulation resulted in a robust citrullination of H3R26 (Fig. 1E). Thus, our data strongly suggest citrullination of H3R26 depends on E2-ER signaling.

We next investigated the dynamics of estrogen-ER-mediated H3R26 citrullination by using another HE-la cell line that contains multiple genomically integrated copies of the estrogen-responsive prolactin (PRL) enhancer/promoter reporter array (Fig. 1F) and a stably expressed ER-GFP-fusion construct (GFP-ER) (15). This line allows for the imaging of GFP-ER binding to the PRL array and subsequent large-scale changes in chromatin structure. Results from previous studies found that E2 stimulation induces an ER-dependent decondensation of the PRL array, thus reflecting a chromatin state similar to that found at endogenous ER target promoters during transactivation. Interestingly, previous studies demonstrated that levels of specific histone acetylation and methylation marks are not greatly altered at the PRL array after E2 stimulation (16). In our study, before E2 stimulation, little citrullination of H3R26 was observed. However, after E2 treatment, a large H3Cit26 foci was found to strongly colocalize with GFP-ER at the decondensed PRL array (Fig. 1F and Fig. S5). Given our recent finding that PAD-dependent histone hypercitrullination results in chromatin decondensation (17), we predicted that the targeting of ER to the PRL array by estrogen likely resulted in E2-mediated recruitment of PADs to the promoter and subsequent PAD-mediated citrullination of H3R26, thus resulting in decondensation of the PRL array.

**ERE Motifs Overlap H3Cit26 Sites at E2-Induced Gene Promoters.**

Given the observed global associations between histone citrullination and estrogen signaling, we next began to investigate the extent to which H3R26 citrullination correlates with ER binding at proximal promoter target regions by conducting ChIP/promoter analysis in MCF-7 cells using a tiling array that covers 2.2 kb upstream and 500 bp downstream, relative to the transcriptional start site of the PRL-based array (16). Xn

![Fig. 1. Estrogen-induced H3R26 citrullination is associated with ER.](image)

(A) IHC analysis of H3Cit26 staining on uterine sections collected from ovariectomized mice implanted with pellets containing either vehicle control or E2 pellets. (Scale bars: 20 μm.) (B–F) Confocal microscopic analyses showing colocalization of H3Cit26 and ER in nucleus of ER-positive MCF-7 cells (B). This colocalization is not observed in either ER-negative MDA-MB231 (C) or HeLa (D) cells upon E2 stimulation. Stable overexpression of ER in HeLa cells (E) restores E2-induced citrullination of H3R26. Merged images highlight H3Cit26 and ER colocalization. (Scale bar: 10 μm.) (F) Colocalization of H3Cit26 and GFP-ER at a decondensed PRL-array in HeLa cells stably overexpressing GFP-ER. Arrows indicate GFP-ER, and arrowheads indicate H3Cit26 foci in the decondensed array after E2 stimulation. (Scale bar: 15 μm.) (G) Inset highlights a single PRL-array locus. (Magnification: 10x.) Yellow arrowhead represents H3Cit26 and GFP-ER (green) staining. Schema in Lower shows the essential elements of the PRL-based array (16). Xn indicates S2 repeats of the elements.
Comparison of citrullination at H3R26 before and after E2 stimulation revealed 208 promoters that contained significantly higher levels of the H3Cit26 modification after E2 treatment (induced), 110 promoters with lower H3Cit26 levels after E2 treatment (reduced), and 55 promoters with no changes in H3Cit26 levels (constitutive) (Fig. 2A and B). To further characterize the putative targets of H3Cit26-regulated gene transcription, we used de novo motif discovery to search for overrepresented motifs within 100 bp of the center of the H3Cit26 peaks (19). This unbiased analysis revealed the presence of a previously published, well-characterized ERE motif (20) (Fig. 2C). The heatmap in Fig. 2D demonstrates that the ERE motif displayed a similar distribution pattern as that of H3Cit26 in the induced group (top left to lower right diagonal), and this pattern was not observed in the noninduced groups (reduced and constitutive). We identified 59 targets (28.4%) as having an ERE in the H3Cit26-induced group, whereas only 8 (4.8%) genes in the noninduced groups contained the ERE motif, thus indicating a 5.9-fold ERE enrichment in the H3Cit26-induced group (Fisher’s exact test, $P = 7.5 \times 10^{-10}$) (Fig. 2C). Collectively, these data support the hypothesis that E2-induced citrullination at H3R26 plays a role modulating the expression of a subset of ER target genes. Given that ER can bind to chromatin through bridging interactions with other transcription factors, such as AP-1, for example, and that these ER binding sites often do not contain underlying EREs (21), it seems likely that the H3Cit26 modification is also enriched at other non-ERE–containing target sites. Additionally, a recent ChIP-seq report found that only ~7% of ER binding sites are within 5 kb upstream of the TSS (22). Given that the proximal promoter arrays used in our study only covered 2.2 kb upstream of the TSS, it seems likely that many ER target sites outside of this region are also citrullinated at H3R26 after E2 treatment.

H3R26 Citrullination Likely Promotes an Open Chromatin Architecture at the EREs of E2-Induced Gene Promoters. A growing body of evidence suggests that specific histone tail modifications function, in part, by “loosening” the chromatin architecture at gene promoters, thus enhancing accessibility for binding factors, such as basal and specific transcription factors and RNA polymerases (2, 5, 7–9). Micrococcal nuclease (MNase) cleaves linker and nucleosome-free DNA, and is, therefore, often used to evaluate the state of chromatin compaction (23, 24). To test the hypothesis that H3R26 citrullination might act to maintain an open chromatin architecture around ERE regions at the promoters of a subset of E2-induced genes, we next examined the accessibility of ERE-containing H3Cit26-bound promoters to digestion by MNase as described (23, 24). We tracked five ER targets from the induced group that contain well-characterized EREs in their promoters, TFF1 (25), KRT13 (26), GREBL (27), WISP2 (28), and CYP1B1 (29, 30) and also two control genes, SASH1 and UBE2H2, which did not show an increase or decrease in citrullination after E2 treatment and do not appear to contain an ERE near the citrullinated site (i.e., the noninduced group). As
expected, E2 treatment caused a significant decrease in MNase protection at the ERE region on the promoters of the E2-induced genes relative to the EtOH control (Fig. 3 A and B and Fig. S6 A–C), and this effect was not observed at the noninduced control promoters (Fig. 3 A and B and Fig. S6 D). This observation suggests that, after E2 treatment, H3R26 citrullination at the ERE regions of E2-induced gene promoters results in a MNase hypersensitivity profile that is indicative of an open chromatin architecture. Moreover, ChIP analysis (Fig. 3 C and D) revealed that, after E2 stimulation, there were marked increases in ER binding and H3R26 citrullination at the ERE regions on target promoters. Although E2 weakly induced the recruitment of ER to SCN1A, increased citrullination at H3R26 was not observed, thus further confirming our promoter array analysis. Taken together, our data suggest that E2-induced citrullination of H3R26 helps to establish an open and active chromatin environment at ER target promoters.

Interdependent PAD2-Catalyzed H3R26 Citrullination and ER Recruitment at Induced Target Promoter EREs Facilitates Target Gene Transcription. We next pretreated MCF-7 cells with the pure ER antagonist, ICI182780, and then performed ChIP to test for potential E2-induced functional interplay between ER and H3R26 citrullination at EREs. As shown in Fig. 4 A and B, although E2 is able to induce both H3R26 citrullination and ER recruitment at TFF1 and KRT13, inhibiting ER blocked not only ER recruitment, but also strongly suppressed H3R26 citrullination at this region. H3R26 citrullination at the SCN1A promoter was not affected by any treatment. These data indicate that E2-induced recruitment of ER to a subset of responsive gene promoter EREs facilitates H3R26 citrullination at these sites.

We then wondered whether decreased H3R26 citrullination could have a similar inhibitory effect on ER recruitment. To address this question, however, we first needed to identify which PAD was responsible for catalyzing H3R26 citrullination. Although most previous reports have documented a role for PAD4 in gene regulation via histone citrullination (12, 13), we have recently found that PAD2 also appears to citrullinate histones in vivo (31). This finding raised the possibility that the observed citrullination at H3R26 might be mediated by PAD2 as opposed to PAD4. To test this hypothesis, we first evaluated the substrate preferences of these enzymes by determining the steady-state kinetic parameters for histones H3 and H4, as well as several peptides whose sequences are based on the N-termini of these peptides whose sequences are based on the N-termini of these

Fig. 3. After estrogen stimulation, H3R26 citrullination facilitates an open chromatin architecture at the EREs of E2-induced gene promoters. (A) MNase protection assay after EtOH and E2 treatment in MCF-7 cells. qPCR was performed to tile through the proximal promoter ERE region with overlapping amplicons (~100-bp PCR product average, with ~20 bp overlap). Relative ratio of the amount of digested DNA to genomic control was used to determine the extent of MNase protection. Values from overlapping primer sets are averaged. Each point represents the mean ± SEM, n = 3. (B) H3Cit26 ChIP-chip signals localize to the proximal promoter ERE regions of E2-induced targets. The shaded region indicates the range tested in A for MNase protection assay. (C and D) ChIP-qPCR analysis of H3Cit26 and ER at target gene promoters after EtOH or E2 treatment in MCF-7 cells. Error bars indicate SEM, n = 3.
proteins and encompass residues known to be citrullinated (Table S1). Analysis of the ratio of catalytic efficiencies \( \frac{k_{\text{cat}}/K_{\text{m}}(\text{PAD2})}{k_{\text{cat}}/K_{\text{m}}(\text{PAD4})} \) reveals that PAD2 citrullinates the H3 (22–30) peptide, which contains H3R26, at a sixfold higher rate than PAD4 (Fig. 4C), indicating that the histone H3R26 residue is a valid PAD2 target in vitro. To test whether PAD2 might target H3R26 in cellulo, we then generated PAD2- (Fig. 4D) and PAD4- (18) depleted MCF-7 cell lines and performed ChIP analysis on the TFF1 and KRT13 promoters. Results from the PAD2-depleted line showed a marked suppression of H3R26 citrullination at TFF1 and KRT13 after E2 stimulation (Fig. 4E). Similar effects, however, were not observed in the PAD4-depleted line (Fig. S7). Taken together, our in vitro and in cellulo findings support our hypothesis that PAD2 (as opposed to PAD4) plays a direct role in citrullinating H3R26 in cells. Importantly, we also found that PAD2 depletion markedly suppressed ER recruitment to EREs at the TFF1 and KRT13 promoters (Fig. 4F). This result indicates that PAD2-mediated citrullination of H3R26 is likely to be involved in recruitment of ER to the ERE.

One interpretation of our cumulative findings is that PAD2-mediated H3R26 citrullination opens the local chromatin architecture, thus facilitating ER recruitment. Alternatively, however, it is also possible that ER recruitment may induce a chromatin remodeling event that, in turn, yields a chromatin template that is accessible to citrullination at H3R26. In light of the recent “assisted loading” hypothesis (32), it is possible that both models are functional and that this dual activity produces a reinforcing loop that ultimately enhances ER binding, that, in turn, recruits the requisite coactivator complexes that create the appropriate chromatin environment for binding by the general transcriptional machinery and RNA polymerase. The interdependent nature of E2-stimulated H3R26 citrullination and ER recruitment at induced gene promoters also suggests a potential association between PAD2 and ER. To test this hypothesis, we first performed communoprecipitation analysis in MCF-7 cells and found that endogenous PAD2 does appear to interact with endogenous ER and that this interaction is enhanced after E2 treatment (Fig. S8A). Reciprocally, we also generated an MCF-7 cell line that stably overexpresses a Flag-tagged version of PAD2 and found that E2 stimulates the interaction between endogenous ER and Flag-PAD2 (Fig. S8 B and C). We note here that the Flag-tagged PAD2 approach was necessary because immunoprecipitation-quality PAD2 antibodies are not available. We then carried out ChIP analysis by using the anti-Flag antibody in this modified MCF-7 cell line and found that, after E2 stimulation, Flag-tagged PAD2 was specifically recruited to the same sites within the ERE region of TFF1 that are bound by ER and contain the H3Cit26 modification (Fig. S8D). The observations that E2-induced chromatin decondensation is closely related to transcriptional activity (33) and that the H3Cit26 modification was primarily observed at the ERE regions of E2-induced genes suggested that PAD2-mediated citrullination of H3R26 at ERE promoter regions facilitates ER-mediated gene transactivation. To test this hypothesis, we investigated whether the transcription of genes, whose promoters were citrullinated after E2 treatment, was affected by either PAD2 depletion or inhibition. As expected, either knockdown of PAD2 (Fig. 4G) or pretreatment of cells with CJ-Amidine, a newly developed arginine-based PAD inhibitor (34) (Fig. 4H), dramatically dampened the ability of these ERE targets to be activated after E2 treatment.

Taken together, our data indicate that PAD2 plays an important role in mediating the activation of ERT target genes via cit- \( \text{H}3R26 \) citrullination of histone H3R26. This activity likely cooperates with other activities such as coactivator binding, chromatin remodeling factor association, and basal transcription factor/RNA polymerase recruitment in establishing an open, permissive, chromatin architecture around the EREs of E2-induced genes, thus facilitating transcriptional activation. These findings help to improve our mechanistic understanding of how ER regulates gene transcription via altering chromatin structure.

### Materials and Methods

**Cell Culture.** Cell culture, shRNA, and Flag-tagged PAD2 overexpression are described in SI Materials and Methods. Before E2 treatment, cells were cultured for 3 d in DMEM phenol-free medium supplemented with 10% charcoal-dextran-treated calf serum. IC182780 was used at 10 \( \mu \)M for 18 h
before the addition of E2. Ci-Amidine was used at 200 μM for 40 h before E2 stimulation.

**Mouse Ovariectomy, E2 Treatment, and Immunohistochemistry (IHC).** All procedures were conducted in accordance with the National Institutes of Health regulations and approved by the Cornell University animal use committee. See *SI Materials and Methods* for detailed protocols.

**Confocal Microscopy.** Cells grown on slides were subjected to E2 treatment for 45 min. Confocal microscopy experiments were described (13). Antibodies used are listed in *SI Materials and Methods*.

**High Content Analysis-Based Immunofluorescence Microscopy.** Stable GFP-ERα: PRL-HeLa cells were E2 starved and then treated with 30 min with either 10 nM E2 or ethanol. Immunofluorescence experiment, fluorescent microscopy image acquisition, and quantitation was performed as described (15).

Nuclear masks were created by using the DAPI channel, and GFP-ER signal was used to define the PRL array mask. Average intensity measurements were taken (>1,000 cells per treatment) for the nucleoplasmic and array H3Cit26 signals (in E2) and normalized to ETOH nucleoplasm H3Cit26 signal.

**ChIP and ChIP-chip.** ChIP experiments were performed as described (18). E2 was used at concentration of 100 nM for 45 min; antibodies and quantitative PCR (qPCR) primers are listed in *SI Materials and Methods*. ChIP for H3Cit26 coupled with hybridization to a human H3Cit26 promoter microarray from Nimblegen and genomic data analyses were performed as described (18). Significant peaks and the “induced,” “reduced,” or “constitutive” regions were defined as described in *SI Materials and Methods*. The TSS-anchored ChIP-chip heat maps were generated using 600-bp windows with 150-bp steps and were visualized with Java Treeview (35). The data can be accessed through the NCBI GEO website by using accession no. GSE32599.

**De Novo Motif Search.** MEME was applied with all default parameters to search for overrepresented motifs (19). A motif width between 6 and 20 bp was specified by using 200-bp windows centered on each of the 208 induced H3Cit26 binding sites. *Table S2* includes the matrix that was found by MEME and subsequently used to make the sequence logo for ERE (Fig. 2C) using the R package “seqLogo” contributed by Oliver Bembom. For the heat map to visualize the ERE distribution, we used a published position-specific weight matrix (20) and searched for the matched that conform with a P value ≤0.0005. The promoters were then scanned into nonoverlapping 50-bp windows and, if an ERE motif was found within a window, the window was colored yellow.

**MNase Protection Assay.** Estrogen-starved MCF-7 cells were treated with ethanol or 100 nM E2 for 45 min, and MNase protection assay was performed as described (23, 24). MNase was from New England Biolabs (M0274). See primers in *SI Materials and Methods*.

**Gene-Specific Expression Analyses.** Estrogen-starved cells were treated with ethanol or 100 nM E2 for 6 h. RNA reverse transcription and quantitative real-time PCR were performed as described (18). Primers used are listed in *SI Materials and Methods*.

**Steady-State Kinetic Assays.** Histone peptides were synthesized by using the Fmoc approach and purified by reverse-phase HPLC. PADS 2 and 4 purification, kinetic assays were performed as described in *SI Materials and Methods*.

**Histone Extraction, PAD Assay, Mass Spectrometry, and Immunoprecipitation Assay.** See *SI Materials and Methods* for detailed protocols.

**ACKNOWLEDGMENTS.** We thank W. L. Kraus for HeLa-ER cells and C. D. Allis for the H3 unmodified peptide. This work was supported by a Department of Defense Era of Hope Scholar Award W871WX-07-0372 (to S.A.C.), and National Institutes of Health Grants GM25232 (to J.T.L.) and GM079357 (to P.R.T.). X.Z. was supported by a Postdoctoral Fellowship KG101030 from the American Cancer Society.

**For Grant Support.** S. Komen for the Cure, and M.B. was supported by Training Fellowship T5SLM00793 from the Keck Center National Library of Medicine of Medicine Train-Q:21 Program in Biomedical Informatics of the Gulf Coast Consortia.


Q: 1. Please contact PNAS_Specialist.djs@sheridan.com if you have questions about the editorial changes, this list of queries, or the figures in your article. Please include your manuscript number in the subject line of all e-mail correspondence; your manuscript number is 201203280.

Q: 2. Please (i) review the author affiliation and footnote symbols carefully, (ii) check the order of the author names, and (iii) check the spelling of all author names, initials, and affiliations. Please check with your coauthors about how they want their names and affiliations to appear. To confirm that the author and affiliation lines are correct, add the comment “OK” next to the author line. This is your final opportunity to correct any errors prior to publication. Misspelled names or missing initials will affect an author’s searchability. Once a manuscript publishes online, any corrections (if approved) will require publishing an erratum; there is a processing fee for approved erratum.

Q: 3. Please review and confirm your approval of the short title: H3R26 citrullination and ERα target transcription. If you wish to make further changes, please adhere to the 50-character limit.

Q: 4. If your article contains links to Web sites (other than the SI links for your article), please verify that the links are valid and will direct readers to the proper Web page.

Q: 5. Author names may have been edited to match those provided during article submission; please check carefully and note your approval in the margin. (Your article cannot be published until your approval has been received.)

Q: 6. Please provide division and/or department for affiliation a.

Q: 7. All key terms were deleted because they repeat terms in the TITLE or ABSTRACT, which are searchable online. Please provide up to 5 new key terms that do not repeat terms present in the title or abstract and do not include nonstandard abbreviations. Because we prefer to avoid publishing a single key term, please add at least two terms (and specify your preferred order in which the terms should appear) if you add any terms.

Q: 8. Please review the information in the author contribution footnote carefully. Please make sure that the information is correct and that the correct author initials are listed. Note that the order of author initials matches the order of the author line per journal style. You may add contributions to the list in the footnote; however, funding should not be an author’s only contribution to the work.

Q: 9. You will receive a notification from the PNAS eBill system in 1-2 days. Each corresponding author is required to log in to the system and provide payment information for applicable publication charges (purchase order number or credit card information) upon receipt of the notification. You will have the opportunity to order reprints through the eBill system if desired, as well. Failure to log in and provide the required information may result in publication delays.

Q: 10. Reminder: You have chosen not to pay an additional $1300 (or $975 if your institution has a site license) for the PNAS Open Access option.
Q: 11_Please indicate whether the data have been deposited in GenBank or another publicly accessible database before your page proofs are returned. It is PNAS policy that the data be deposited BEFORE the paper can be published.

Q: 12_PNAS italicizes the names of genes and alleles. Please check throughout the manuscript and correct as necessary. If, by “XXX gene,” you mean “the gene that encodes protein XXX,” then italic type is not necessary.

Q: 13_Please verify that all supporting information (SI) citations are correct. Note, however, that the hyperlinks for SI citations will not work until the article is published online. In addition, SI that is not composed in the main SI PDF (appendices, datasets, movies, and “Other Supporting Information Files”) have not been changed from your originally submitted file and so are not included in this set of proofs. The proofs for any composed portion of your SI are included in this proof as subsequent pages following the last page of the main text. If you did not receive the proofs for your SI, please contact PNAS_Specialist.djs@Sheridan.com.

Q: 14_PNAS does not allow statements that work is planned or in progress; the statement “This hypothesis will be further tested in the future” has thus been deleted.

Q: 15_PNAS does not allow statements that work is planned or in progress; the statement “and more comprehensive ChIP-seq experiments are currently underway to test this hypothesis” has thus been deleted.

Q: 16_PNAS does not allow statements of novelty or priority. Please approve deletion of “previously unknown” in “Taken together, our data indicate that PAD2 plays an important role in mediating the activation of ER target genes via citrullination of histone H3R26.”.

Q: 17_PNAS does not allow statements that work is planned or in progress; the statement “Studies are currently underway to further dissect the mechanism by which the H3Cit26 modification is regulated and its possible role in tumorigenesis” has thus been deleted.

Q: 18_Please state basis for all concentrations >1% (eg, vol/vol)

Q: 19_Please provide the name of the “animal use committee.”

Q: 20_Please provide affiliation and affiliation location (city and state/country) for Oliver Bembom.

Q: 21_Please confirm whether the spellout of NLM is correct.
Supporting Information

Zhang et al. 10.1073/pnas.1203280109

SI Materials and Methods

Cell Culture and E2 Treatments. MCF-7 cells were maintained in DMEM supplemented with 10% calf serum. The PAD2-depleted MCF-7 cell line was generated by transfection of MCF-7 cells with a Mission shRNA Plasmid DNA containing a short hairpin RNA (shRNA) construct targeting the human PAD2 coding sequence (Sigma; SHCLND-NM_007365) using FuGENE6 (Roche). The stable PAD4-depleted MCF-7 cell line was described (1). In the control group, cells were transfected with a nontargeting shRNA control vector (Sigma SHC002). Cells were selected by medium containing 1 μg/mL puromycin (Sigma). Flag-tagged PAD2 overexpression MCF-7 cells were generated by transfection with Flag-PAD2-pcDNA3.1 (+) and selected by medium containing 0.5 μg/mL puromycin. HeLa-ER cells were kindly provided by W. Lee Kraus (University of Texas Southwestern Medical Center, ). HeLa, HeLa-ER, and MDA-MB231 cells were maintained in DMEM supplemented with 10% FBS. Before E2 treatment, the cells were cultured for 3 d in DMEM phenol red-free medium supplemented with 10% charcoal-dextran-treated calf serum. IC182780 was used at 10 μM for 1 h before the addition of E2.

Mouse Ovariectomy (OVX), E2 Treatment, and Immunohistochemistry (IHC). Female nu/nu nude mice (4-wk-old; The Jackson Laboratory) were ovariectomized and simultaneously implanted with s.c. estrogen pellets (0.72 mg per pellet, 60-d release; Innovative Research of America) or a sham control pellet (n = 3 per group). The mice were killed 3 wk after treatment. Uterine tissue was excised, fixed in 10% buffered formalin, embedded in paraffin, sectioned, and stained with anti-H3Cit26 antibody (Abcam; ab19847, lot 135757).

Confocal Microscopy. Cells grown on slides were subjected to E2 treatment for 45 min. Confocal microscopy experiments were described (2). Antibody used were as follows: anti-H3Cit26 (Abcam; ab19847, lot 135757), anti-H3Cit2/8/17 (Abcam; ab77164), H4Cit3 (Millipore; 07–596), Ac-H4K5 (Abcam; ab51997), H3K9 dimethyl (Abcam; ab1220), H3K27 trimethyl (Abcam; ab6002), and ERα (Abcam; ab2746). Images were collected with LSM 510 laser scanning confocal microscope (Carl Zeiss).

Chromatin Immunoprecipitation (ChIP) and ChIP-chip. ChIP experiments were performed as described (1). Estrogen was used at concentration of 100 nM for 45 min. Antibodies used were anti-H3Cit26 (Abcam; ab19847, lot 135757), anti-ERα (Santa Cruz; sc-542), and anti-Flag (Sigma; F3165). Primers used for the ChIP-qPCR were listed as below. ChIP for H3Cit26 coupled with hybridization to a human H3G18 RefSeq promoter microarray from Nimblegen, and genomic data analyses were performed as described (1). The log2 ratio (IP/Input) data from each array was subjected to Lowess normalization (3). The normalized data were scaled to equivalent sum of squares and then the between-array mean log2 ratio was determined for each probe. An error model was generated by using a 1-kb moving window with 250-bp steps in which both the mean probe log2 ratio and P values were calculated for each window. The P values were calculated by using the nonparametric Wilcoxon signed-rank test. Significant peaks were defined as the center of three consecutive windows with positive means, the center window with a mean greater than either adjacent window, and all windows having significant P value less than 0.016. Induced regions were defined as H3Cit26-bound regions (present in the E2-treated samples) that had both a significant P value and a fold ratio >1.148 compared with the EtOH samples. Reduced regions were defined as H3Cit26-bound regions (present in the EtOH control samples) that had both a significant P value and a fold <1 compared with the E2-treated samples. Constitutive regions were defined as H3Cit26-bound regions (present in both conditions) that did not have a significant P value form the composite fold analysis. The TSS-anchored ChIP-chip heat maps were generated by using 600-bp windows with 150-bp steps and were visualized with Java Treeview (4). The data can be accessed through the NCBI/GEO website by using accession number GSE32599.

Steady-State Kinetic Assays. PAD2 was purified by established methods (5, 6). PAD4 was purified as described (7). Histone-based peptides were synthesized by using the Fmoc approach and purified by reverse-phase HPLC to ≥95%. Kinetic assays were performed as described (8). Briefly, reaction buffer (100 mM Tris-HCl at pH 7.6, 2 mM DTT, 10 mM CaCl2, and 50 mM NaCl) was preincubated for 10 min at 37 °C with varying concentrations of histone H3 (0–180 μM), or peptide (22–30) (0–10 mM). The reaction was initiated by the addition of enzyme (0.2 μM final). After 6 min, reactions were quenched by flash freezing in liquid nitrogen, and 200 μL of COLDER solution was added to each tube. The absorbance at 540 nm was quantitated and product formation determined by comparing the absorbance to a citrulline standard curve. The data were fit to the following equation: v = Vmax[S]/(Km+[S]) by using the GraFit version 5.0.11 software package (9).

Acid Extraction of Histones, PAD Assay, and Western Blotting. MCF-7 cells were first E2 starved, followed by 100 nM E2 treatment for 45 min. EtOH treatment was used as a control. Cellular histones were purified by acid extraction (2). For the PAD assay, human PAD2 proteins were expressed and purified from pET6-PAD2 by using Ni-NTA Protein Purification System (Qiagen). The PAD assay was performed as described (2). Histone samples were separated by 15% SDS/PAGE, and the membrane was detected by Western blot using anti-H3Cit26 (ab19847, lot 135757), and anti-H3 (Abcam; ab1791).

Identification of Arg26 Citrullination in Human Histone H3 by nanoLC/MS/MS Analysis Using LTQ Orbitrap Velos. The PAD2-treated H3 bands were excised from gel and subjected to digestion and extraction as reported (10). The digest was reconstituted in 10 μL of 2% acetonitrile (ACN) with 0.5% formic acid (FA) for nanoLC-ESI-MS/MS analysis, which is carried out by using a LTQ-Orbitrap Velos (Thermo-Fisher Scientific) mass spectrometer equipped with “Plug and Play” nano ion source device (CorSolutions). The nanoLC was carried out by Dionex UltiMate3000 MDLC system (Dionex). The tryptic peptides (5–10 μL) was injected onto a PepMap C18 trap column at 20 μL/min flow rate and then separated on a PepMap C18 RP nano column, which was installed in the Plug and Play device with a 10-μm spray emitter (New Objective) mounted in front of Orbitrap orifice. The peptides were then eluted in a 90-min gradient of 10–40% ACN in 0.1% FA at 300 nL/min, followed by a 3-min ramping to 95% ACN-0.1% FA and a 5-min holding at 95% ACN-0.1% FA. The column was reequilibrated with 2% ACN-0.1% FA for 20 min before the next run. The Orbitrap Velos was operated in positive ion mode with nanospray voltage set at 1.5 kV and source temperature at 275 °C. Either internal calibration using the background polysiloxane ion signal at m/z 445.120025.
as a lock mass or external calibration using Ulrimark 1621 for Fourier Transform (FT) mass analyzer was performed. The instrument was performed in parallel data-dependent acquisition (DDA) mode by using FT mass analyzer for one survey MS scan for precursor ions followed by MS/MS scans on the top seven most intensity peaks with multiple charged ions above a threshold ion count of 7,500 in both LTQ mass analyzer and HCD-based FT mass analyzer at 7,500 resolution. MS survey scans at a resolution of 60,000 (FWHM at m/z 400), for the mass range of m/z 375–1800. Dynamic exclusion parameters were set at repeat count 1 with a 20-s repeat duration, exclusion list size of 500, 30-s exclusion duration, and ±10 ppm exclusion mass width. Collision induced dissociation (CID) parameters were set at the following values: isolation width 2.0 m/z, normalized collision energy 35%, activation Q at 0.25, and activation time 10 ms. The activation time is 0.1 ms for HCD analysis. All data are acquired under Xcalibur 2.1 operation software (Thermo-Fisher Scientific). The database search was performed with three-missed dynamic carbamidomethyl modification of cysteine, variable modifications on methionine oxidation, asparagine/glutamine deamidation, lysine acetylation/methylation, and arginine citrullination were set. The peptides with low confidence score (with Xcorr score <2 for doubly charged ion and <2.7 for triply charged ion) defined by PD1.2 were filtered out, and the remaining peptides were considered for the peptide identification with possible modification determinations. All MS/MS spectra for possibly modified peptides identified from initial database searching were manually inspected and validated by using both PD1.2 and Xcalibur 2.1 software.

**Immunoprecipitation Assay.** MCF-7 cells and MCF-7 cells stably overexpressing Flag-tagged PAD2 were estrogen starved for 3 d followed by 100 nM E2 stimulation for 45 min at 37 °C. The whole-cell lysates were immunoprecipitated with anti-ER or anti-Flag M2 affinity gel (Sigma; A2220). Immunoprecipitates were analyzed by Western blot using anti-PAD2 (ProteinTech; TFF1c-Fwd 5′-CTCTGGATTAAGGTCAGGTTGGA-3′, and anti-Flag antibodies as indicated.

**Primers for ChIP-qPCR, RT-qPCR, and MNase Protection-qPCR.**

<table>
<thead>
<tr>
<th>ChIP-qPCR</th>
<th>RNA-qPCR</th>
<th>MNase protection-qPCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>TFF1-Fwd 5′-AGCTGCTGAGTCCTCGAGCAAG-3′</td>
<td>TFF1-Rev 5′-TCGTGGATGACCTGAGCAAG-3′</td>
<td>TFF1-Fwd 5′-CTCTGGATTAAGGTCAGGTTGGA-3′</td>
</tr>
<tr>
<td>TFF1-Fwd 5′-AGGAGGGGCTGAGAAATGTTA-3′</td>
<td>TFF1-Rev 5′-AGCTGCTGAGTCCTCGAGCAAG-3′</td>
<td>TFF1-Rev 5′-GAGAGGCACACCGAGATGATG-3′</td>
</tr>
<tr>
<td>TFF1-Fwd 5′-GCCAATGCTTCCTCCTTTC-3′</td>
<td>TFF1-Rev 5′-GAGAGGCACACCGAGATGATG-3′</td>
<td>TFF1-Fwd 5′-GCATGGAAACGTGGAAAGAA-3′</td>
</tr>
<tr>
<td>TFF1-Fwd 5′-TCTCAGATCGCCTCAGCCAAG-3′</td>
<td>TFF1-Rev 5′-GCATGGAAACGTGGAAAGAA-3′</td>
<td>TFF1-Fwd 5′-AAAGGTCAGGTTGGAGGAGAC-3′</td>
</tr>
<tr>
<td>TFF1-Fwd 5′-CCCTGGACGCACTCAGAGATG-3′</td>
<td>TFF1-Rev 5′-AAAGGTCAGGTTGGAGGAGAC-3′</td>
<td>TFF1-Rev 5′-TGAGGAGTGATCTGAGTGGAG-3′</td>
</tr>
<tr>
<td>TFF1-Fwd 5′-CTCTGGATTAAGGTCAGGTTGGA-3′</td>
<td>TFF1-Rev 5′-TGAGGAGTGATCTGAGTGGAG-3′</td>
<td>TFF1-Fwd 5′-TGAGGAGTGATCTGAGTGGAG-3′</td>
</tr>
</tbody>
</table>

**RT-qPCR:**

| TFF1-Fwd 5′-CATCGACGTCCCTCCAGAGAG-3′ | TFF1-Rev 5′-TCTCGGGACTAATCCCGGTCTG-3′ | TFF1-Fwd 5′-CATCGACGTCCCTCCAGAGAG-3′ |
| TFF1-Fwd 5′-GCGAGAGATGAGGGAGGACGTA-3′ | TFF1-Rev 5′-TCTCGGGACTAATCCCGGTCTG-3′ | TFF1-Fwd 5′-CATCGACGTCCCTCCAGAGAG-3′ |
| TFF1-Fwd 5′-GAGGAGGGCTGAGAAATGTTA-3′ | TFF1-Rev 5′-GAGGAGGGCTGAGAAATGTTA-3′ | TFF1-Fwd 5′-CATCGACGTCCCTCCAGAGAG-3′ |
| TFF1-Fwd 5′-GAGGAGGGCTGAGAAATGTTA-3′ | TFF1-Rev 5′-GAGGAGGGCTGAGAAATGTTA-3′ | TFF1-Fwd 5′-CATCGACGTCCCTCCAGAGAG-3′ |

**Mnase protection-qPCR:**

| TFF1a-Fwd 5′-TCTCGGGACTAATCCCGGTCTG-3′ | TFF1b-Rev 5′-TCTCGGGACTAATCCCGGTCTG-3′ | TFF1a-Fwd 5′-TCTCGGGACTAATCCCGGTCTG-3′ |
| TFF1a-Fwd 5′-TCTCGGGACTAATCCCGGTCTG-3′ | TFF1b-Rev 5′-TCTCGGGACTAATCCCGGTCTG-3′ | TFF1a-Fwd 5′-TCTCGGGACTAATCCCGGTCTG-3′ |

Zhang et al. www.pnas.org/cgi/content/short/1203280109 2 of 9


**Fig. S1.** E2 induced global activation of H3R26 citrullination in MCF-7 cells. (A) In the absence of E2 treatment (EtOH control), H3Cit26 signals (red) are very weak. After 45 min of E2 treatment, elevated levels of nuclear H3R26 citrullination are observed. (Scale bar: 10 μm.) (B) Western blot showing that amounts of H3Cit26 were increased in MCF-7 cells after E2 treatment. Blotting with anti-Histone H3 (Lower) revealed that histone levels between groups were similar.

**Fig. S2.** Estrogen treatment does not appear to globally affect levels of other histone modifications in MCF-7 cells. Confocal immunofluorescence images show that the signals for H4Cit3 (A), H3Cit28/17 (B), Ac-H4K5 (C), me2-H3K9 (D), and me3-H3K27 (E) signals do not appear to change after E2 stimulation. (Scale bars: 10 μm.)
Fig. S3. Time course of E2-induced global H3R26 citrullination in MCF-7 cells. Confocal immunofluorescence microscopic images showing that treatment of estrogen-starved MCF-7 cells with 100 nM of E2 results in H3R26 citrullination within 5 min and that the signal peaked at 45 min after E2 treatment. (Scale bar: 10 μm.)

Fig. S4. H3Cit26 antibody specificity. (A) Specificity of the anti-H3Cit26 antibody was tested with peptide competition assay. Western blot showing that the anti-H3Cit26 antibody is specifically reactive with the appropriately sized band from human PAD2-treated MCF-7 cell histones but not from nontreated histones. Anti-H3Cit26 antibody was preincubated with 1 μg/mL H3Cit26 immunogen peptide (Abcam; ab20631) overnight at 4 °C before Western blot analysis. The competing peptide nearly completely blocked detection of H3Cit26. Anti-histone H3 staining revealed the presence of approximately equal amounts of histone in each lane. (B) The positive band in A was subjected to MS/MS analysis. Citrullination at R26 of the tryptic peptide AARKSAPATGGVK from human histone 3 was detected by nanoLC-MS/MS analysis. MS/MS spectrum of the doubly charged peptide ions at m/z 628.8510 with elution time at 32.55 min shows almost all y-ion series and b-ion series, demonstrating that R26 residue was converted to Citrulline (Arg > Cit) with increased 0.98402 Da. Meanwhile, K27 was identified as being acetylated (42.01057 Da). The MS/MS spectrum was searched against human database by using Proteome Discoverer 1.2 software with integrated SEQUEST searching engine with XCorr:3.75, and Probability:51.10. (C) ChIP analysis showing that H3Cit26 enrichment on TFF1 promoter is specifically competed by the H3Cit26 immunogen peptide. Anti-H3Cit26 antibody was mock- (PBS incubation) or preincubated with 1 μg/mL H3Cit26 immunogen peptide (Abcam; ab20631), H3Cit2/8/17 immunogen peptide (Abcam; ab32876), or unmodified histone H3 (19–38) overnight at 4 °C. IgG was used as a control.
Fig. S5. Quantitation of H3Cit26 at the PRL-array. The histogram shows relative intensity for the anti-H3Cit26 signal in E2-treated nucleoplasm (E2 Nuc) and E2-treated array (E2 Array) compared with EtOH treated nucleoplasm (EtOH Nuc). P values were calculated based on the basis of two-tailed Student t test.
After estrogen stimulation, H3R26 citrullination facilitates an open chromatin architecture at the EREs of E2-induced gene promoters. In each graph, $\text{GREB1}$ (A), $\text{WISP2}$ (B), $\text{CYP1B1}$ (C), or $\text{VAT1L}$ (D), upper shows the MNase protection assay following EtOH or E2 treatment in MCF-7 cells. qPCR was performed to tile through the proximal promoter ERE region with overlapping amplicons (~100-bp PCR product average, with ~20-bp overlap). Relative ratio of the amount of digested DNA to genomic control was used to determine the extent of MNase protection. Values from overlapping primer sets are averaged. Each point represents the mean $\pm$ SEM, $n = 3$. Lower shows the H3Cit26 ChIP-chip signal at the proximal promoter ERE region of E2-induced target.

Zhang et al. www.pnas.org/cgi/content/short/1203280109
Depletion of PAD4 does not inhibit H3Cit26 enrichment on TFF1 ERE region. Depletion of PAD4 (PAD4 KD) from MCF-7 cells was described (3). E2 treatment induced the pronounced enrichment of H3Cit26 on the TFF1 ERE region in the shRNA control MCF-7 cells, whereas this increase was not observed in the PAD4 depleted line.

Fig. S8. E2 stimulates the association of PAD2 with ER at the ERE region on TFF1. (A) Coimmunoprecipitation analysis in wild-type MCF-7 cells reveals that E2 treatment stimulates the interaction between endogenous PAD2 and ER. (B) Western blotting documenting PAD2 overexpression. EV represents the empty vector control. β-actin (Lower) revealed equal protein loading. (C) Coimmunoprecipitation analysis of MCF-7 cells stably overexpressing Flag-PAD2 reveals that E2 treatment stimulates the interaction between endogenous ER and ectopically expressed PAD2. (D) Ectogenic PAD2 is recruited to TFF1 ERE promoter region after E2 treatment. ChIP assay with anti-Flag antibody on the TFF1 tilling promoter regions in the MCF-7 cells stably overexpressing PAD2. E2 stimulation induced PAD2 recruitment to the ERE region.
Table S1. Steady-state kinetic parameters for histone H3 and H4 substrates

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Substrate</th>
<th>$k_{cat}$ s$^{-1}$</th>
<th>$K_m$ mM</th>
<th>$k_{cat}/K_m$ s$^{-1}$M$^{-1}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAD2</td>
<td>H3</td>
<td>ND*</td>
<td>ND*</td>
<td>1,200</td>
</tr>
<tr>
<td></td>
<td>H3 (1–15)</td>
<td>2.4 + 0.10</td>
<td>1.9 + 0.25</td>
<td>1,250</td>
</tr>
<tr>
<td></td>
<td>H3 (22–30)</td>
<td>1.4 + 0.17</td>
<td>3.7 + 1.0</td>
<td>370</td>
</tr>
<tr>
<td></td>
<td>H4</td>
<td>ND*</td>
<td>ND*</td>
<td>2,400</td>
</tr>
<tr>
<td></td>
<td>H4 (1–15)</td>
<td>1.4 + 0.1</td>
<td>1.0 + 0.2</td>
<td>1,400</td>
</tr>
<tr>
<td>PAD4</td>
<td>H3</td>
<td>ND*</td>
<td>ND*</td>
<td>3,700</td>
</tr>
<tr>
<td></td>
<td>H3 (1–15)</td>
<td>0.6 + 0.03</td>
<td>3.3 + 0.4</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td>H3 (22–30)</td>
<td>ND*</td>
<td>ND*</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>H4</td>
<td>1.2 + 0.2‡</td>
<td>0.1 + 0.03‡</td>
<td>9,000‡</td>
</tr>
<tr>
<td></td>
<td>H4 (1–15)</td>
<td>2.5 + 0.1</td>
<td>0.6 + 0.1</td>
<td>4,400</td>
</tr>
</tbody>
</table>

Kinetic parameters were measured by incubating the enzyme at 37 °C.
*ND, not determined due to a lack of saturation in the $v$ versus $[S]$ curves.
†Value taken from ref. 1.
‡Value taken from ref. 2.

Table S2. ERE matrix file found by MEME from the 208 E2-induced H3Cit26 binding sites

<table>
<thead>
<tr>
<th></th>
<th>&quot;A&quot;</th>
<th>&quot;C&quot;</th>
<th>&quot;G&quot;</th>
<th>&quot;T&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.048780</td>
<td>0.000000</td>
<td>0.658537</td>
<td>0.292683</td>
</tr>
<tr>
<td>2</td>
<td>0.000000</td>
<td>0.073171</td>
<td>0.926829</td>
<td>0.000000</td>
</tr>
<tr>
<td>3</td>
<td>0.000000</td>
<td>0.000000</td>
<td>0.000000</td>
<td>1.000000</td>
</tr>
<tr>
<td>4</td>
<td>0.000000</td>
<td>1.000000</td>
<td>0.000000</td>
<td>0.000000</td>
</tr>
<tr>
<td>5</td>
<td>1.000000</td>
<td>0.000000</td>
<td>0.000000</td>
<td>0.000000</td>
</tr>
<tr>
<td>6</td>
<td>0.073171</td>
<td>0.585366</td>
<td>0.341463</td>
<td>0.000000</td>
</tr>
<tr>
<td>7</td>
<td>0.414634</td>
<td>0.292683</td>
<td>0.121951</td>
<td>0.170732</td>
</tr>
<tr>
<td>8</td>
<td>0.000000</td>
<td>0.341463</td>
<td>0.487805</td>
<td>0.170732</td>
</tr>
<tr>
<td>9</td>
<td>0.146341</td>
<td>0.000000</td>
<td>0.000000</td>
<td>0.853659</td>
</tr>
<tr>
<td>10</td>
<td>0.073171</td>
<td>0.195122</td>
<td>0.682927</td>
<td>0.048780</td>
</tr>
<tr>
<td>11</td>
<td>0.243902</td>
<td>0.170732</td>
<td>0.292683</td>
<td>0.292683</td>
</tr>
<tr>
<td>12</td>
<td>0.170732</td>
<td>0.829268</td>
<td>0.000000</td>
<td>0.000000</td>
</tr>
<tr>
<td>13</td>
<td>0.000000</td>
<td>0.634146</td>
<td>0.000000</td>
<td>0.365854</td>
</tr>
<tr>
<td>14</td>
<td>0.097561</td>
<td>0.121951</td>
<td>0.097561</td>
<td>0.682927</td>
</tr>
<tr>
<td>15</td>
<td>0.024390</td>
<td>0.243902</td>
<td>0.243902</td>
<td>0.487805</td>
</tr>
</tbody>
</table>
AUTHOR QUERIES

Q: 1. Please confirm whether the renumbering of citations and references in SI Materials and Methods has been done correctly.

Q: 2. Please note that courtesy titles are deleted except in Acknowledgments as per PNAS style. Also, please provide affiliation location for University of Texas Southwestern Medical Center.

Q: 3. Please state basis for all concentrations >1% (eg, vol/vol).

Q: 4. Quotation marks are used at the first appearance of a word or phrase; they do not appear with each subsequent use of that word or phrase.

Q: 5. Per PNAS style, references not cited in the SI text have been removed from the SI reference list (which has been renumbered accordingly) and placed with the legends of the SI figures or tables in which they are cited. Note that these references are numbered independently in each table or figure. Please check these citations carefully.

Q: 6. Please provide column header for column 1 in Table S2.